Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | TP53 | P04637 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217688 | 1.00 | LMNA (0.66) | LMNATP53MAPTMEN1KMT2A | |
| SCHEMBL6215343 | 0.87 | — | — | |
| SCHEMBL6215340 | 0.87 | — | — | |
| SCHEMBL6215609 | 0.82 | LMNA (0.67) | LMNATP53MAPTMEN1KMT2A | |
| SCHEMBL6219085 | 0.81 | LMNA (0.45) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL6604629 | 0.80 | LMNA (0.69) | LMNATP53MEN1KMT2A | |
| SCHEMBL6604625 | 0.80 | LMNA (0.69) | LMNATP53MEN1KMT2A | |
| SCHEMBL6601294 | 0.78 | TP53 (0.62) | LMNATP53MAPTMEN1KMT2A | |
| SCHEMBL6601296 | 0.78 | TP53 (0.62) | LMNATP53MAPTMEN1KMT2A | |
| SCHEMBL8165384 | 0.77 | LMNA (0.64) | LMNATP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884310-B1 | Quinazolin-4-one ampa antagonists | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6921764-B2 | Thieno-pyrimidin-4-one AMPA antagonists | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6627755-B1 | Neurodegenerative, psychological, and nervous system disorder; drug abuse, alcoholism | PFIZER INC | 2003-09-30 | — | — | US | disclosed |
| EP-0884310-A1 | Quinazolin-4-one ampa antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | GRIN1, GRIK1, GRIN3A | LMNA 4699/4885TP53 4570/4885MAPT 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.